AFMD: Affimed Therapeutics Growth-Adjusted Market Cap to Net Income
The development of immunotherapy via NK-cell activation is stimulating capital inflows, which validates the calculated PEG ratio for Affimed (AFMD). This parameter has stabilized at 0.00, reflecting the current market valuation. Growth prospects are based on the robotization of antibody screening using AI and strict adherence to European biosafety standards for the disposal of laboratory materials.
Metric breakdowns and analytics for Affimed (AFMD)
- share price and consensus valuation forecast:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
AFMD - Net Profit|Forward Earnings Affimed|AFMD - P/E Multiple|Market Cap to Projected Earnings affimed.com|AFMD - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Affimed Therapeutics|AFMD - Operating profit EBITDA|Net earnings per one share for the last twelve months Affimed|AFMD - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months affimed.com|AFMD - Earnings growth in current year|Earnings growth forecast for next year Affimed
General company analysis:AFMD - Affimed NV
Affimed (AFMD) creates high added value through its proprietary bispecific antibody technology, which is reflected in the stock's valuation via the PEG ratio. This indicator compares the price-to-earnings multiple with the earnings growth rate: a value below one signals that the asset is undervalued relative to business dynamics, allowing investors to identify the potential for a sharp surge in share prices while maintaining a fundamental margin of safety.
Competing companies
ARGX (argenx N.V.) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (BioNTech Group)|Growth-Adjusted Market Cap to Net Income Abivax (ABVX)|ADMA - Price/Earnings to Growth Ratio|protagonist-inc.com (PTGX) - Price/Earnings to Growth Multiple|Immunovant (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals, Ltd.|Price/Earnings to Growth Multiple GRFS|PEG Multiple Adaptive Biotechnologies Inc.|Price/Earnings to Growth Ratio Celldex Therapeutics (CLDX)|auriniapharma.com - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - Price to Earnings Adjusted for Growth Rate|Dianthus Pharma - PEG Multiple|PHVS - PEG Multiple|ABCL: PEG Multiple|Market Cap to Earnings and Growth Ratio TRML (tourmalinebio.com)|PGEN (Precigen) - PEG Multiple|Pharming Group NV - Market Cap to Earnings and Growth Ratio|PEG Multiple NKTR|Growth-Adjusted Market Cap to Net Income Upstream Pharma|Price/Earnings to Growth Ratio Zenas Biopharma Inc ZBIO|IMNM - Price/Earnings to Growth Multiple|Gossamer Bio - PEG Multiple|Price to Earnings Adjusted for Growth Rate KalVista Pharma|SEPN: PEG Multiple|Growth-Adjusted P/E Ratio PVLA|SVRA (Savara Inc.) - PEG Multiple|PEG Multiple rigel.com|PEG Multiple ANAB|ATXS: Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio enGene Bio ENGN|RAPT - Price/Earnings to Growth Multiple|Aerovate - PEG Multiple|ACRS (aclaristx.com) - Growth-Adjusted P/E Ratio|Kyverna Therapeutics, Inc. (KYTX) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio TLSA (Tiziana Life Sciences Ltd.)|CABA (Cabaletta Bio, Inc) - PEG Multiple|VTYX: Growth-Adjusted Payback Ratio|PEG Multiple THTX|PEG Multiple avalotx.com (AVTX)|Price/Earnings to Growth Ratio Eledon Pharmaceuticals, Inc. ELDN|Growth-Adjusted Payback Ratio AGEN|CLYM - Price/Earnings to Growth Ratio|zurabio.com (ZURA) - Price/Earnings to Growth Multiple|ATYR: PEG Multiple|Adagene Inc. (ADAG) - PEG Multiple|Price/Earnings to Growth Multiple IMA|STTK: Growth-Adjusted Payback Ratio|PEG Multiple EQ|Growth-Adjusted Market Cap to Net Income connectbiopharm.com|Price/Earnings to Growth Ratio Immunic IMUX|ATRA - Price/Earnings to Growth Multiple|IFRX - Price/Earnings to Growth Ratio|X4 Pharmaceuticals Inc. (XFOR) - Price/Earnings to Growth Multiple|ACET (adicetbio.com) - Price/Earnings to Growth Multiple|Celularity (CELU) - PEG Multiple|Price/Earnings to Growth Ratio INmune Bio, Inc.|Growth-Adjusted P/E Ratio BRNS (barinthusbio.com)|PEG Multiple KZR|SABS - Price to Earnings Adjusted for Growth Rate|PEG Multiple AKTX (Akari Therapeutics plc)|PEG Multiple Enlivex Therapeutics Ltd ENLV|Q32 Bio Corp - PEG Multiple|Market Cap to Earnings and Growth Ratio GOVX|EDSA: PEG Multiple|Market Cap to Earnings and Growth Ratio IBIO (iBio Inc)|CARM (Carisma Therapeutics Inc) - PEG Multiple|XTL Bio (XTLB) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Bolt Biotherapeutics (BOLT)|Price/Earnings to Growth Multiple hcwbiologics.com HCWB|PEG Multiple APVO (Aptevo Therapeutics Inc.)|aimimmuno.com (AIM) - Price to Earnings Adjusted for Growth Rate|Aditxt Corp - PEG Multiple|GRI (GRI Bio Corporation) - Growth-Adjusted P/E Ratio|XRTX: PEG Multiple|reshapelifesciences.com (HIND) - PEG Multiple|REVB (Revelation Biosciences, Inc.) - PEG Multiple|Indaptus Therapeutics Inc - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio Scinai (SCNI)|Price/Earnings to Growth Multiple calcimedica.com CALI|PEG Multiple ALLK (Allakos)|HOOK: Growth-Adjusted P/E Ratio|IGMS - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio ITOS|OCEA: PEG Multiple|TC BioPharm Ltd - Growth-Adjusted Payback Ratio|THRD (Third Harmonic Bio) - PEG Multiple
